explore -WSS

explore

author：knowledge 2025-09-29 21:28:37 - browse：876

ADAM FEUERSTEIN/STAT

CHICAGO — Corbus Pharmaceuticals is the second best-performing biotech stock this year, thanks to investor interest in an antibody-drug conjugate candidate, or ADC, called CRB-701 with the potential to be better tolerated than Padcev, an ADC treatment bladder cancer that Pfizer acquired as part of its $43 billion Seagen deal.

On Saturday, Corbus updated results from an early, dose-finding study of CRB-701, showing an overall response rate of 28% from 25 evaluable patients. Closer attention is being paid to the subset of 15 patients treated at three therapeutically active doses, where the overall response rate (all partial tumor shrinkage) was 40%. All of the responses were seen in bladder cancer (where Padcev is approved) and in cervical cancer.

The data, from a study conducted in China, were presented in a poster session at the annual meeting of the American Society of Clinical Oncology.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

focus

WSS

STAT Boddities: What happens to the brain when we get scared?

Report cites 'urgent' need to recruit more diverse clinical trial participants

TytoCare raises $49 million to build out AI

White House drug shortage group privately met with industry

Having children helps parents live longer, especially after age 80

Tome Biosciences co

Wikipedia

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

BioMarin wins approval for gene therapy to treat hemophilia A

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Heart attack and stroke risk calculators need revising

Study gives hint on South Asians’ higher risk of cardiovascular disease

Guidelines to prevent youth baseball injuries need more muscle

Wild otter attack leads to woman being airlifted to hospital, 2 others treated for injuries

Sports medicine is finally prioritizing gender equality

Congress considering partial increase for doctor pay in Medicare

Moonlake's readout produced a cash windfall. Risks remain

Doctors on social media are being harassed and cyberbullied

explore

ER docs worry over extreme heat as a 'mass casualty event'

Congress must protect the remaining independent doctors

Stem cell clinics for heart failure: buyer be wary

Too many hospitalized Covid

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Dramatically reducing cancer deaths requires the PASTEUR Act

focus

focus

focus

leisure time